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SMO. SMO in turn signals to the GLI family of transcription factors and thus induces a change in the transcriptional profile of the cell (4) . Inappropriate activation of the pathway, most often caused by inactivating mutations in PTCH, or activating mutations in SMO, is associated with cancer, predominantly BCC and MB (5) (6) (7) (8) .
Vismodegib binds to, and inhibits SMO, blocking downstream Hh pathway activation.
In early-stage clinical studies, a MB patient from the Hh sub-group harboring widespread metastatic disease, exhibited rapid and dramatic tumor regression when treated with vismodegib (9) . Unfortunately, the robust initial response was followed by relapse, reminiscent of the acquired resistance seen in the context of other targeted therapies, such as erlotinib (10) . Sequence analysis of a tumor biopsy obtained after progression in this patient indentified an amino acid substitution at a conserved residue of SMO. The D473H substitution disrupts the ability of vismodegib to bind SMO, but does not alter the ability of SMO to activate the Hh pathway (11) . This observation triggered a series of investigations into potential alternative mechanisms of resistance against vismodegib and sonidegib, another Hh pathway inhibitor currently under clinical development (12) . A variety of resistance mechanisms were identified through the use of mouse models, including additional mutations in Smo, as well as downstream Hh pathway alterations such as Gli2 amplification (11, 13, 14) . An additional, and unexpected potential mechanism of acquired resistance to sonidegib was the up-regulation of PI3K signaling (13) .
The PI3K pathway is a well-established oncogenic pathway that regulates cell growth, proliferation, and survival by relaying growth factor signaling (15) 6 the PI3K pathway occurs in multiple tumor types and is frequently driven by disruptions in the negative pathway regulator PTEN, but can also be driven by gain-of-function mutations in PIK3CA. A recent genomic analysis of MB tumors revealed that of 13 Hh sub-group patients profiled, two had loss of function mutations in PTEN, and another patient had an activating mutation in PIK3CA (16) . Of 66 patients profiled from the other sub-groups, none had loss of PTEN, and two had mutations in PIK3CA. Another sequencing study likewise found a number of PTEN mutations in medulloblastoma tumors, one of which co-occurred with a homozygous PTCH mutation (17) . In addition to genomic alterations as a mechanism to hyperactivate the PI3K pathway, epigenetic inactivation of PTEN has been reported to occur at a high frequency in MB samples (18) . Given that inappropriate activation of PI3K signaling may represent a potential mechanism of acquired resistance to Hh pathway inhibitors, we wanted to determine if pre-existing PTEN mutations, which occur in Hh subgroup patients, would alter the initial response to vismodegib in Hh-driven MB. 
Materials and Methods

Mouse models
Math1 CreER and Pten loxp mouse strains were both obtained from The Jackson Laboratory (stock numbers 007684 and 004597, respectively), and the Ptch loxp strain was a kind gift from R. Toftgard and S. Teglund (Karolinska Institutet) (19) . All mice were housed and maintained according to the animal use guidelines of Genentech, conforming to California State legal and ethical practices. Cre-dependent recombination was induced by oral gavage of tamoxifen (single dose of 4 mg in sunflower seed oil) to pregnant dams at E14.5.
Tissue analysis
Tumors were harvested from moribund animals and subject either to overnight fixation in 4% paraformaldehyde prior to embedding in paraffin, or to lysis in CelLytic MT Lysis reagent (Sigma). Immunohistochemistry (IHC), immunofluorescence (IF), and western blotting (WB) were carried out according to standard procedures. Antibodies used were as follows: mouse anti-NeuN (1:500 for IF and 1:1000 for WB; Millipore, # MAB377), rabbit anti-Ki67 (1:300, Thermo Scientific, # RM9106), rabbit anti-pAKT S473 (1:500 for IHC and 1:1000 for WB, Cell Signaling Technology, # 4060), rabbit anti-pS6 (1:1000, Cell Signaling Technology, # 4858), rabbit anti-PTEN (1:100 for IHC and 1:1000 for WB, Cell Signaling Technology, # 9188) and rabbit anti-cleaved caspase 3 (1:100 for IHC, Cell Signaling Technology, # 9661). The DAKO Envision+ HRP (DAB) system was used to detect primary 
Generation of MB allografts and drug treatments
To enable an assessment of the sensitivity of these MB models to inhibition of the Hh and PI3K pathways, tumor growth was relocated subcutaneously via grafting. The cerebella of mice displaying symptoms associated with MB were harvested and prepared for subcutaneous inoculation into the right lateral thorax of female CD1-nude (CRL) mice aged at least 6 weeks, to establish passage 1. Allografts were generated via inoculation of a single cell suspension in 100 µl Neuralbasal Medium (Invitrogen) (PM model, derived from (baseline) and in relation to the vehicle. As such, a TGI value of 100% indicates tumor stasis; a TGI value of >1% but <100% indicates tumor growth delay; and a TGI value of >100% indicates tumor regression and would be associated with a negative AUC.
To determine uncertainty intervals (UIs) for %TGI, the fitted curve and the fitted covariance matrix were used to generate a random sample as an approximation to the distribution of %TGI. The random sample is composed of 1000 simulated realizations of the fitted−mixed model, in which the %TGI is recalculated for each realization. Our reported UI is the value for which 95% of the time the recalculated values of %TGI will fall in this region given the fitted model. The 2.5 and 97.5 percentiles of the simulated distribution were used as the upper and lower UIs, respectively. All TGI values were calculated at day 13 of the experiment, to allow for direct comparison across the two models; TGI cannot be calculated beyond day 13 in the PPM model as control/vehicletreated tumor-bearing animals were euthanized before the end of the study, because tumor volumes exceeded 2000 mm 3 .
Results
Loss of PTEN accelerates the onset of morbidity in a mouse model of Hh-driven MB
An earlier study showed that deletion of Ptch in cerebellar granule neural precursor cells survival, with a median of 7.4 weeks (Fig. 1A) Analysis of brain samples from PM and PPM mice revealed very large tumors within the cerebellum, which disrupt the normal cerebellar architecture (Fig. 1B, C, D) . Histologically, tumors from PM mice resemble classic MB, which is the histological sub-type that predominates amongst human patients from the Hh sub-group; these are frequently described as "small round blue-cell" tumors (Fig1 C). In contrast, tumors from PPM mice have a markedly different appearance, with a histological phenotype analogous to medulloblastoma with extensive nodularity (MBEN), which in humans, is a histological subtype thought to be restricted to Hh sub-group patients (3). Tumors from PP wt/loxp M mice are histologically indistinguishable from PPM tumors, with a MBEN appearance (Suppl. Fig.   1 ). The cerebella of Ptch wt/wt ; Pten loxp/loxp ; Math1 CreER mice lack tumors, however, we did detect large ectopic cells both external to, and within the molecular layer (Suppl. Fig. 2 ).
Activation of PI3K signaling drives MB cells towards a more differentiated phenotype
Immunohistochemical analysis revealed additional differences between PM and PPM tumors. PM tumors are largely made up of undifferentiated cells, positive for Ki67 and negative for the neuronal marker NeuN (Fig. 2A , see also Suppl. Fig. 3 (Fig. 2B , and Suppl. Fig. 3 for pH3 IHC) . These proliferative stripes appear to localize to perivascular regions (see Fig. 2C inset) , an observation that was confirmed by EdU/CD31 double-staining, in tumors harvested 2 hours after administration of the thymine analog (Fig. 2D) . PM tumors have a relatively high level of baseline apoptosis, as revealed by the presence of cleaved caspase 3 (CC3), which appeared to be markedly reduced in PPM tumors (Fig. 2E, F) . We used image analysis to quantify this apparent difference, taking into account the observation that in any field of view there appear to be more cells in the PM model than in the PPM model, and found that indeed, apoptosis is significantly suppressed in the PPM model (Fig. 2G , see also Suppl. Fig. 4 for an illustration how the image analysis was conducted).
Loss of PTEN in Hh-driven MB alters the response of tumors to vismodegib
The early onset of tumors in the PM and PPM models, the very rapid onset of morbidity of the PPM model in particular, and the lack of normal cerebellar tissue in this model, which would be required to maintain cerebellar functionality after targeting the tumor, prevented us from performing a vismodegib intervention study in the autochthonous setting.
Fortunately however, the value and relevance of allograft studies in the context of MB have previously been well established (11, 13, 14) . Therefore, to evaluate the response of PM and PPM tumors to vismodegib, we generated allograft models; tumors harvested from PM 
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and PPM animals were passaged subcutaneously in nude mice. This allowed tracking of tumor volumes over time, in response to various doses of drug (see also Methods).
Although the histological characteristics distinguishing primary PM and PPM tumors do not appear to be strictly maintained in the allograft setting, key features, such as PTEN status and pAKT levels (Fig. 3A, B) , are maintained. Note the loss of PTEN in PPM tumor cells, but not in stromal cells, consistent with the restriction of cre-recombinase activity to Math1-expressing neural progenitors. As expected, loss of PTEN is associated with robust upregulation of pAKT. In addition, PPM allografts appear to retain a somewhat more differentiated phenotype when compared to PM allografts, with apparent increases in NeuN levels (Fig. 3C) , though the differentiation phenotype is less dramatic in the allografts when compared to the primary tumor.
Oral gavage of mice with 3 mg/kg vismodegib QD has little effect on allograft growth, in either model, despite having a modest effect on Hh pathway activity (Fig. 4A, B, D) . This finding, that ~50% Hh pathway inhibition is not sufficient to drive a tumor response, is consistent with the recent demonstration that sustained and robust inhibition of the Hh pathway (>80%) is required for a meaningful anti-tumor effect (23) . In contrast, 30 mg/kg vismodegib QD is sufficient to cause a meaningful growth delay in both models, with a mean tumor growth inhibition (TGI) of 90% in the PM model, and 70% in the PPM model (Fig. 4A, B, C) .
Interestingly, the response to vismodegib appears to diverge between the models at higher doses of vismodegib. In the PM model, vismodegib dosed at 60 mg/kg and 90 mg/kg QD 14 results in rapid and robust tumor regression, with 149% and 159% mean TGI respectively; tumors continued to regress beyond day 13, and were barely detectable at day 21, when the study ended (Fig. 4A, C) . In contrast, PPM tumors had not regressed by day 13, on either 60 mg/kg or 90 mg/kg vismodegib, with a mean TGI of less than 100% in both cases (87% and 90%); rather, these doses achieved tumor stasis by the end of the study, despite a comparable level of Hh pathway inhibition (Fig. 4D) .
Combined PI3K and Hh pathway inhibition drives tumor regression in the PPM model
GNE-317 is a PI3K/mTOR pathway inhibitor that was specifically designed to cross the blood-brain barrier, with the treatment of PI3K pathway-driven glioblastoma as the primary objective (24) . We made use of this previously described compound to ask if inhibition of the Hh pathway in combination with inhibition of PI3K signaling, would improve on vismodegib as a single agent. GNE-317 when dosed at 30 mg/kg QD successfully attenuates PI3K signaling in the allograft setting, as measured by pS6 levels (Fig. 5A) , and by pAKT levels (Suppl. Fig. 5 ), but does not alter levels of Hh pathway activity (Fig. 4D) . Likewise, 90 mg/kg vismodegib does not influence activation of the PI3K pathway in this setting (Suppl. Fig. 5 ). GNE-317, as a single agent, achieved modest inhibition of tumor growth in the PM model, and a more meaningful inhibition of growth in the PPM model (mean TGI 37% and 66% respectively) (Fig. 5B, C, D) . In the PPM model, while vismodegib treatment alone did not drive regression at any concentration tested, GNE-317 treatment, when combined with either 60 mg/kg or 90 mg/kg vismodegib, resulted in tumor regression (Fig. 5B, D) . At 60 mg/kg vismodegib plus GNE-317, mean tumor volume at the study start was 232 mm 3 , which regressed to 152 mm 3 on day 13 and 100 mm 3 by the study endpoint. At 90 mg/kg vismodegib plus GNE-317, mean tumor volume at the study start was 244 mm 3 , which regressed to 102 mm 3 on day 13 and 80 mm 3 by the study end. It is also worth noting that the regression driven by the combination of GNE-317 plus 90 mg/kg vismodegib is highly consistent across individual tumors/animals (Fig. 5D ).
Discussion
Inherited mutations in PI3K signaling components are associated with human syndromes that include neurological abnormalities, such as Lhermitte-Duclos disease, indicating that this pathway is important in normal neural development and/or function (25) . Indeed, two independent mouse studies described the use of Gfap Cre to delete Pten in the brain, and showed that this led to lethal neurological defects including seizures and ataxia, which were coupled to an enlargement of the cerebellum (25, 26) . Histological analysis revealed the presence of ectopic, enlarged cells at the pial surface and within the molecular layer of the cerebellum, which was attributed to a migration defect in mutant cells. Histologically, this phenomenon is very similar to the phenotype seen in Ptch wt/wt ; Pten loxp/loxp ; Math1 CreER mice, though the mice described here do not display any overt clinical symptoms, potentially due to incomplete deletion of PTEN driven by the Math1 CreER (see Suppl. Perhaps most relevant, the RCAS/tv-a system, which allows postnatal gene transfer in a cell type specific manner, was used to generate MB by targeting SHH to nestin-expressing neural stem cells, either in the presence or absence of PTEN (28) . Intriguingly, PTEN deficient tumors were described as having MBEN histology, with high levels of NeuN, very similar to the PPM model described here. Moreover, the perivascular niche of these tumors was described as being highly proliferative, "in fact the only proliferative region in the tumors", again, very similar to the PPM model described here. We propose that these for descriptions of Hh pathway inhibitors currently under clinical development]. In the case of BCC, for which vismodegib is now approved, the vast majority of tumors display alterations in the Hh pathway, and there is no current requirement for the stratification of patients. However, the additional genomic complexity seen in MB patients means that it will be critical to pre-select the ~25% of patients who are defined as the Hh sub-group. Based on the data described here, we now argue that it will also be important to monitor PI3K pathway status during patient selection, particularly in cases where a positive clinical trial outcome is defined by regression, rather than stasis. The diagnostic strategy, which will enable the selection of patients who may respond to Hh pathway inhibitors as a single agent, versus those who might benefit from a combined regime of a Hh pathway inhibitor plus a brain penetrant PI3K inhibitor, will require careful consideration, given that PI3K pathway alterations in MB have been reported not only at the genomic, but also at the 
